BPI 421286
Alternative Names: BPI-421286Latest Information Update: 14 Jun 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Jun 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in China (PO) (Betta Pharmaceuticals pipeline, June 2024)
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 24 Aug 2021 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in China (PO) (NCT05315180)